Cargando…
Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)
BACKGROUND: Uridine 5′‐diphospho‐glucuronosyltransferase 1A1 (UGT1A1*27) is known to impair the effect of UGT in basic research; however, little clinical investigation has been conducted. To evaluate the effect of the UGT1A1*27 polymorphism in irinotecan therapy, we conducted a prospective study. ME...
Autores principales: | Fukuda, Minoru, Suetsugu, Takayuki, Shimada, Midori, Kitazaki, Takeshi, Hashiguchi, Kohji, Kishimoto, Junji, Harada, Taishi, Seto, Takashi, Ebi, Noriyuki, Takayama, Koichi, Sugio, Kenji, Semba, Hiroshi, Nakanishi, Yoichi, Ichinose, Yukito |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930967/ https://www.ncbi.nlm.nih.gov/pubmed/27385990 http://dx.doi.org/10.1111/1759-7714.12360 |
Ejemplares similares
-
Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1
*
28 or *
6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A)
por: Fukuda, Minoru, et al.
Publicado: (2016) -
Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4‐ALK fusion gene
por: Kometani, Takuro, et al.
Publicado: (2018) -
A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)
por: Wakuda, Kazushige, et al.
Publicado: (2020) -
Digitale Logik
por: Stuckenberg, Hans Joachim
Publicado: (1970) -
Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801
por: Takayama, Koichi, et al.
Publicado: (2020)